Dr. Abi-Jaoudeh Discusses Potential of Immunotherapy in Advanced HCC

Nadine Abi-Jaoudeh, MD
Published Online: Thursday, Apr 20, 2017



Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma (HCC).

Immunotherapy, and the combination of immunotherapy with locoregional therapy, could be effective in the field of advanced HCC, says Abi-Jaoudeh.

Currently, sorafenib (Nexavar) is the only FDA-approved frontline treatment for HCC. Abi-Jaoudeh says that leaves a huge space for combinations of immunotherapy and locoregional therapy to flourish.
 

<<< View more from the 2017 International Liver Congress



Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma (HCC).

Immunotherapy, and the combination of immunotherapy with locoregional therapy, could be effective in the field of advanced HCC, says Abi-Jaoudeh.

Currently, sorafenib (Nexavar) is the only FDA-approved frontline treatment for HCC. Abi-Jaoudeh says that leaves a huge space for combinations of immunotherapy and locoregional therapy to flourish.
 

<<< View more from the 2017 International Liver Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 29, 20172.0
Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary CancersApr 29, 20172.5
Publication Bottom Border
Border Publication